3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Gynecologic
1
Gastrointestinal
1
Conditions
Colorectal Neoplasms
21
Anus Neoplasms
17
Carcinoma, Hepatocellular
11
Appendiceal Neoplasms
11
Stomach Neoplasms
10
Neoplasm Metastasis
9
Peritoneal Neoplasms
8
Pancreatic Neoplasms
8
Colonic Neoplasms
6
Rectal Neoplasms
5
Liver Neoplasms
5
Anal Canal Carcinoma
4
Ovarian Neoplasms
3
Gastrointestinal Neoplasms
3
Uterine Neoplasms
2
Pseudomyxoma Peritonei
2
Uterine Cervical Neoplasms
1
Sarcoma
1
Recurrence Hepatocellular Carcinoma
1
Recurrence
1
Pleural Neoplasms
1
Peritoneal Diseases
1
Neoplasms, Squamous Cell
1
Neoplasms
1
Necrosis
1
Mesothelioma
1
Mediastinal Neoplasms
1
Locally Advanced Anal Canal Cancer
1
Hyperthermia
1
HIV Infections
1
Interventions
pembrolizumab
12
Nivolumab
6
Cyclophosphamide
6
fludarabine
5
Ipilimumab
4
amatuximab
3
Cisplatin
3
tislelizumab
2
spartalizumab
2
fludarabine phosphate
2
budigalimab
2
belinostat
2
Plicamycin
2
Hyperthermic Intraperitoneal Chemotherapy
2
Fluorouracil
2
Cytoreduction Surgical Procedures
2
venetoclax
1
tocilizumab
1
talazoparib
1
sotorasib
1
rovalpituzumab tesirine
1
obinutuzumab
1
niraparib
1
naptumomab estafenatox
1
milademetan
1
irinotecan sucrosofate
1
epacadostat
1
enzalutamide
1
durvalumab
1
defactinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mesothelioma
×
Mitomycin
×
Gastrointestinal
×
Clear all
NCT00454519
2009-02-13
IPHC
Wuhan University
Phase 2
Unknown
60 enrolled